Atlast Bio

Latest news

1. 27 Oct
   Swiss AI drug‑trial startup Atlast Bio raises $12.5M led by Creandum

   Atlast Bio, a Swiss startup that runs drug trials on virtual patients, raised $12.5 million in a funding round led by Creandum. The company says its AI foundation model, trained on about two million human RNA readouts, could replace Phase II trials with 12‑week simulations and expects results from a first trial within six weeks.

   Deals · 1 source

   

Articles

No articles about Atlast Bio yet.